TOUCH® CMC 1 New Enrollment US Study

TOUCH® CMC 1 (Carpometacarpal) Prosthesis is a cementless, ball-and-socket dual-mobility, total CMC1 joint replacement prosthesis, designed to treat osteoarthritis of the base of the thumb. The TOUCH® CMC 1 Prosthesis was approved by FDA (P240020) on July 10, 2025. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post Approval Study Report per the requirements set forth in the approval.

Inclusion criteria

• Patient requiring 1st carpometacarpal (CMC) primary total joint replacement (arthroplasty) to surgically treat symptomatic Eaton-Littler Stage II or III osteoarthritis (OA)
• Adult (≥ 22 years of age) at the time of enrollment
• Willing and able to sign the study Informed Consent

Exclusion criteria

• Acute or chronic infections, local or systemic
• Muscular, neurological, or vascular severe deficiency affecting the joint
• Inadequate bone quality or quantity preventing the implant fixation
• Bones dimensions incompatible with implant sizes
• Patients who are allergic to the product's materials
• Any concomitant disorder that may affect the function of the implant (e.g., osteoarthritis of the wrist)
• Skeletally immature (i.e., pediatric population, <22 years of age)
• Pregnant or nursing women
• Patients with contraindications to surgery in general
• Patients with an intellectual disability who cannot follow the instructions of their surgeon.